Novartis AG (ADR) (NYSE:NVS)
| CAPS Rating |
|
|---|---|
| Open | $55.72 |
| Previous Close | $56.35 |
| Daily Range | $55.66 - $55.96 |
| 52-Week Range | $51.60 - $64.82 |
| Market Cap | $135.62B |
| P/E Ratio | 13.60 |
| Dividend (Yield) | 2.09 (2.70%) |
| Volume | 2,067,430 |
| Average Daily Volume | 0 |
NVS
VS S&P 500 (SPY)
How do you think NVS will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
NVS Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
NVS News and Commentary
- Incyte in Neutral Lane - Analyst Blog – NASDAQ
- All Good Things Must Come to an End – The Motley Fool
- 1 Biotech to Buy Post-Plunge – The Motley Fool
- Buy, Sell, or Hold: Ariad Pharmaceuticals – The Motley Fool
- Generic Challenge for UTHR's Remodulin - Analyst Blog – NASDAQ
- US Judge Rules For FDA In Generic Lovenox Case – SmartMoney
- 1 Cheap Biotech Small-Cap With Huge Potential – The Motley Fool
- The Disadvantage of a Successful Pipeline – The Motley Fool
- Ten Big Pharma Stocks’ Juicy Dividend Payouts, With Cash-on-Hand as Cushion – YCharts
- Maximum Market: $2.9 Billion, For Now – The Motley Fool
- Risk-Reward Balances for Endo Pharma - Analyst Blog – NASDAQ
- Risk-Reward Balances for Endo Pharma - Analyst Blog – NASDAQ
- Risk-Reward Balances for Endo Pharma - Analyst Blog – NASDAQ
- Best Dividend Paying Stock List For February 2012 – Trefis
- The Zacks Analyst Blog Highlights: Pfizer, Biogen Idec, Elan, Novartis and Roche - Press Releases – NASDAQ
- FDA Grants Novartis Cancer Drug Added Approval – SmartMoney
- Kidney Cancer? There's a Drug for That – The Motley Fool
- 2 More Victims of Market Volatility – The Motley Fool
- EPS Beat for Biogen; Outlook Weak - Analyst Blog – NASDAQ
- WSJ BLOG/Health: A.M. Vitals: J&J Shakes Up Oversight of Consumer Unit – SmartMoney
RSS Headlines
Fool UK
